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Abstract
Aims: To identify clinicopathological features and outcomes in patients with late relapse (LR) of testicular germ cell tumours 
(GCTs) in order to guide follow-up policy.
Materials and Methods: The Edinburgh Cancer Centre (ECC) database identiﬁ  ed all patients diagnosed with testicular 
GCT between 1988 and 2002. Of 703 patients, six relapsed more than 24 months after their initial treatment. A retrospective 
casenote review was performed to extract clinical, pathological, treatment and outcome data.
Results: Six patients (0.85%) underwent late relapse. All patients presented initially with stage I disease and ﬁ  ve were 
classiﬁ  ed as good risk (International Germ Cell Consensus Classiﬁ  cation, IGCCC). Median time to LR was 31 months. Two 
patients had previously relapsed less than 24 months from initial diagnosis. Markers at the time of relapse were normal in 
all patients. In all cases of late relapse disease was conﬁ  ned to axial lymphadenopathy. Three patients were treated with 
chemotherapy alone, two patients underwent surgical resection and one patient received combined treatment. All patients 
obtained a complete response and all remain disease free with a median follow-up of 52 months.
Conclusions: The incidence of late relapse in this series is low. Chemo-naive patients with LR were successfully salvaged 
with chemotherapy alone and patients previously exposed to cisplatin-based chemotherapy were salvaged with complete 
surgical excision. The optimal length of follow-up in patients with testicular germ cell tumours is not known and practice 
varies widely. In this cohort of 703 patients, only one patient who relapsed was picked up by additional clinic follow-up 
between 5 and 10 years. Thus, on the basis of this small series, the authors suggest that follow-up after ﬁ  ve years may not 
be justiﬁ  ed.
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Introduction
Testicular germ cell tumours (GCTs) are rare, accounting for only 1% of all male cancers. However, 
they are the most common solid tumours in young men with a peak incidence at 25–35 years [Dearnely, 
2001]. The highest incidence is in northern European males [Devesa, 1995] and approximately 1400 
new cases are diagnosed annually in the United Kingdom. The worldwide incidence has more than 
doubled over the past 40 years for reasons that remain unclear. Testicular maldescent is a recognized 
aetiological factor with a relative risk (RR) of 4.8, familial testicular cancer constitutes a RR of 3–10 
and ipsilateral testicular germ cell cancer results in a 25-fold increased risk of developing a second GCT 
in the contralateral testis [Dieckmann, 2004].
Cure rates for this disease are high although decrease with increasing stage and worsening prognos-
tic group at presentation. [Bhatia, 2000; Miller, 1997; IGCCC 1997]. Relapse rates vary between 10% 
and 30%, depending on the stage of disease with most relapses occurring within 2 years, the majority 
of patients being salvaged with further treatment [Howard, 2005].
A minority of patients (2%–3%) will undergo a “Late Relapse” (LR), deﬁ  ned as metastatic disease 
arising two or more years after completion of primary therapy in the absence of a metachronous GCT 20
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or second non-testicular primary cancer. The time 
to late relapse has been reported to range from 2 
to 32 years with a median of approximately 6 years 
[IGCCC 1997]. Although late relapses of GCT 
have been reported in the chest, neck, pelvis, 
brain, and liver, the most common site is the ret-
roperitoneum, regardless of initial stage, clinical 
presentation, or prior treatment [Baniel, 1995]. 
Alpha-fetoprotein (αFP) is the most frequently 
raised tumour marker, though frequently αFP, beta 
human chorionic gonadotrophin (β-hCG) and 
lactate dehydrogenase (LDH) are all normal.
We have previously published the management 
and outcomes of a cohort of 703 patients diagnosed 
at the ECC between 1988 and 2002 with Germ Cell 
Tumours of the testis [Howard, 2005]. In order to 
develop guidance on longterm follow-up schedul-
ing we studied the further management and out-
comes of a subgroup of these patients who, after 
achieving a complete response, subsequently 
relapsed after a gap of 24 months or more.
Patients and Methods
The ECC database identiﬁ  ed all patients diagnosed 
with testicular GCT between 1988 and 2002 who 
relapsed at or more than 24 months after comple-
tion of primary therapy (orchidectomy with or 
without chemotherapy or radiotherapy). Casenotes 
were examined to extract clinical, pathological, 
mode of treatment and outcome data.
Results
From 1988 to 2002, 703 patients presented to the 
ECC with testicular GCT. Six patients (0.85%) 
relapsed at or more than 24 months after their 
initial treatment.
Features at initial presentation
of primary testicular GCT (Table 1)
The median age of the six patients at the time of 
their initial diagnosis was 39 years (range; 24 to 
51). All patients presented initially with stage I 
disease (Royal Marsden Hospital staging classiﬁ  -
cation [Peckham, 1971]) and five were in the 
IGCCC good prognostic group [IGCCC 1997]. 
One patient was in the intermediate prognostic 
group.  All patients underwent initial trans-inguinal 
orchidectomy. Histopathological examination of 
the primary tumour revealed malignant teratoma 
intermediate (MTI) in three patients, mixed semi-
noma/non-seminomatous germ cell tumour (GCT) 
in one patient and seminoma in two patients.
At initial diagnosis serum markers were normal 
in three cases. The β-hCG was elevated in one 
patient (11150 U/L), and the αFP elevated in two 
patients (115 and 387 kU/L).
Of the two patients with seminoma, one was 
treated with para-aortic strip radiotherapy (30 Gy 
in 15 fractions over three weeks) as per the Edin-
burgh Cancer centre protocol at that time. The 
second patient could not be treated with radiotherapy 
because of severe thoracolumbar kyphosis and thus 
went into a surveillance protocol. Four patients with 
nonseminomatous germ cell tumours (NSGCT) 
were followed up on our surveillance protocol.
Patterns of relapse
Of the whole cohort of 703 patients diagnosed with 
primary testicular GCT, 446 (63%) had seminoma 
and 257 (37%) non-seminoma. 26% initially pre-
sented with metastatic disease. Overall, 42 patients 
relapsed within 2 years of completion of initial 
treatment. The management and outcomes of 
these patients have been described previously 
Table 1. Primary presentation and management.
 Initial  presentation
Patient  1 2 3 4 5  6
Royal Marsden   I  I  I  I  I  I
hospital stage
Initial pathology  MTI  Mixed  Seminoma  Seminoma  MTI  MTI
Markers elevated  αFP  βHCG No  No  αFP No
Treatment after   Surveillance  Surveillance  Surveillance  Para-aortic   Surveillance  Surveillance
orchidectomy      XRT
Abbreviation: MTI: Malignant teratoma intermediate.21
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[Howard, 2005]. Two of these 42 patients (4.7%) 
subsequently relapsed a second time and are 
described here. (Table 1, patients 5 and 6).
In both cases the initial presenting pathology 
was MTI and the site of early relapse was the ret-
roperitoneum. Both patients were asymptomatic 
at the time of initial relapse and the diagnosis was 
made by routine surveillance CT scanning.
Treatment of these two patients at ﬁ  rst relapse 
involved 4 cycles of chemotherapy with bleomy-
cin, etoposide and cisplatin (BEP), followed by 
surgical excision of residual masses with retro-
peritoneal lymph node dissection (RPLND). 
Histopathology revealed teratoma differentiated 
(TD) in both cases. Complete surgical excision 
was identiﬁ  ed pathologically, and biochemical 
and radiological complete response (CR) was 
conﬁ  rmed.
For the six patients patients who relapsed more 
than 24 months after initial diagnosis the median 
time to relapse was 31 months (range; 24 to 135); 
in two patients relapse occurred more than ten years 
after primary treatment. (Table 1).
Three late relapses were identified during 
scheduled follow up, in two patients retroperitoneal 
disease was identified on CT scanning, and in 
one a chest X ray detected a mediastinal mass. Three 
patients required an unscheduled clinic attendance 
for symptomatic disease whilst still on routine follow 
up. All three had cervical lymphadenopathy and a 
staging CT scan conﬁ  rmed additional retroperitoneal 
disease in one patient. Serum tumour markers were 
normal in all patients at the time of LR including 
three patients who were marker positive at primary 
diagnosis.
Management of late relapse (Table 2)
Three patients who were chemotherapy naïve were 
treated with chemotherapy alone, (4 cycles of BEP 
in one patient and 4 cycles of EP in two patients). 
All achieved a radiological complete response and 
have not required further treatment. Two patients 
underwent a surgical resection which revealed 
mature teratoma undifferentiated, one containing 
a small focus of adenocarcinoma. In both cases 
resection was considered to be complete and nei-
ther patient received post surgical chemotherapy. 
In the third patient a resected neck node conﬁ  rmed 
metastatic seminoma and he subsequently received 
four cycles of EP chemotherapy.
After treatment all six patients obtained a com-
plete pathological, biochemical and radiological 
response. All patients remain alive and disease free 
with a median follow up of 52 months (range 
20–136 months).
Table 2. Late relapse presenting features initial management and management at relapse.
     Late  relapse
Time to LR from 1
ο  24  27 135 28  33  135
Treatment (months)
Time to LR from  n.a.  n.a.  n.a.  n.a.  21  105
ER (months)
Mode of diagnosis  CT  CT  Clinical  Clinical  Clinical  CXR
Markers  at  LR  NEG NEG NEG NEG NEG  NEG
Site of LR  Para-aortic  Para-aortic  Para-aortic +   Neck  Neck  Mediastinum
     Neck
LR pathology  None  None  Seminoma  Seminoma  TD  TD with
        ADENOCA
LR  treatment  Chemo Chemo Chemo  Surgery  +    Surgery Surgery
       Chemo
Response  to  CR CR CR CR CR  CR
treatment
     Outcome
Follow up (months)  54  136  50  90  20  30
Outcome  NED NED NED NED NED  NED
Abbreviations: n.a.: not applicable; NEG: Negative; TD: Teratoma Differentiated; MTI: malignant teratoma 
intermediate; CR: Complete Chemoresponse; NED: No evidence of disease.22
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Discussion
Orchidectomy is curative in many early stage tes-
ticular cancers. The introduction of platinum-based 
chemotherapy in the late 1970s dramatically 
improved the outcome for patients with metastatic 
disease. 10%–30% of patients relapse within the 
ﬁ  rst two years following primary management and 
many are salvaged with surgery with or without 
chemotherapy. Historically a complete remission, 
lasting more than two years, was felt to represent 
a cure. However, more recently it has become 
apparent that in a small number of patients (2%–
3%) late relapse may occur up to thirty years after 
initial treatment [IGCCC 1997]. Late relapses may 
represent a distinct clinical subgroup of testicular 
GCTs. Primary testicular GCTs are usually rapidly 
progressive and respond well to chemotherapy; 
however, late relapses frequently respond less well 
to platinum-based chemotherapy, particularly if 
initial treatment included systemic therapy 
[George, 2003].
Review of literature
A Pubmed search of the current literature on late 
relapse identiﬁ  ed nearly 400 cases reported in six 
retrospective studies [Baniel, 1995; Gerl, 1997; 
Shahidi, 2002; Dieckmann, 2002; George, 2003; 
Ronnen, 2005] (Table 3) and several smaller series 
[Terebelo, 1983; Ravi, 1997; Carver, 2005; 
Geldart, 2006].
Dieckmann et al. [Dieckmann, 2005] retrospec-
tively analyzed 122 patients with late relapse, from 
24 institutions in Germany. The median time to 
late relapse was 49.5 months. 61% of LRs were 
detected incidentally during routine follow up and 
12% of all patients with late relapse in this series 
had previously presented with an earlier relapse. 
60% of patients received surgery alone or as a 
component of their treatment of LR and 63% 
remained free from subsequent recurrence with an 
unreported length of follow-up.
Indiana University Medical Centre [Baniel, 
1995] reported 81 late relapses from 1979 to 1992, 
of which 35 occurred in patients who originally 
presented with stage I disease. They showed a 
disease-free survival rate of 25.9% after a median 
follow up of 4.8 years. In this report only 2 patients 
treated with chemotherapy alone remained disease 
free at 12 and 102 months of follow up, compared 
with 68.7% of patients treated with surgical resec-
tion, at a median follow up of 14 months. George 
et al. [George, 2003] reviewed 83 further cases of 
LR, treated at the same centre from 1993 to 2000. 
41% of patients treated with surgery alone remained 
free from subsequent relapse, with a median follow 
up of 37 months, whilst only 15.6% of men who 
received chemotherapy alone remained continu-
ously disease-free at a median follow up of 44 
months.
Shahidi et al. [Shahidi, 2002] identified 53 
patients with LR. In a multivariate analysis, posi-
tive tumour markers at initial presentation and the 
presence of TD in post-chemotherapy surgical 
specimens were predictive of late recurrence. They 
suggested that follow-up to detect recurrence may 
not be required after 5 years, except in those pre-
senting with metastatic non-seminomatous germ 
cell tumours of the testis where lifelong follow-up 
was recommended.
At MSKCC [Carver, 2005], with a median 
follow-up of 42 months, 21 of 50 patients (42%) 
remained disease free following surgical resection 
(with or without prior chemotherapy) for late 
relapse. Predictors of survival after therapy for late 
relapse of GCT included complete surgical resec-
tion, single site of disease and histological ﬁ  nding 
of TD in the resection specimen.
Ronnen et al. [Ronnen, 2005], recently presented 
29 patients with non-seminomatous GCTs treated 
with chemotherapy at LR. In this series the median 
time to late relapse was 10.5 years and the median 
survival was 23.9 months. In 72% of cases LR was 
detected by symptomatic presentation. With a 
median follow-up of 50.6 months, 7 patients 
achieved a sustained complete response, six of them 
had received surgical resection of residual masses.
Gerl et al. [Gerl, 1997] reviewed 25 patients 
with LR and reported a disease-free survival rate 
of 36% at a median follow up of 38 months. At 
diagnosis of LR serum αFP was increased in 67% 
of patients. In this series patients previously 
presenting with an early relapse had a cumulative 
risk of late relapse of 9.4% at 5 years and 29% at 
10 years.
Patients who relapse late, either on surveillance 
or after initial treatment appear to represent a sub-
group with risk factors being a previous relapse 
and TD in post-treatment resected masses. The 
median time to LR is approximately 6 years. Most 
series demonstrate that surgical resection is associ-
ated with improved outcome, though chemo-naive 
patients may be cured with chemotherapy alone 
[Papadimitris, 1997].23
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This ECC series of late relapses in testicular 
GCTs is limited to a small number of patients. The 
incidence rate of 0.85% is lower than in most other 
reported series [Baniel, 1995; Shahidi, 2002; 
Carver, 2005]. The ECC receives few extra-
regional referrals, this therefore represents a true 
population-based incidence and is similar to the 
rate of 1.3% recently reported in a Norwegian 
cohort [Oldenburg, 2006]. As described in other 
published series, NSGCT was found to have a 
higher incidence of LR than seminoma. Four 
patients relapsed whilst on surveillance and 2 after 
a previous earlier relapse. It is of interest that no 
patients who presented with metastatic disease 
relapsed late. Unlike many other series in which 
tumour markers were raised in up to three-quarters 
of patients, αFP and β-hCG levels were normal at 
LR in all of these cases.
One patient had a resection specimen containing 
elements of adenocarcinoma. This is in line with 
a series published by Lutke Holzik et al. where 
14% of recurrences contained non-germ cell malig-
nancy [Lutke Holzik, 2003]. Sarcomas and adeno-
carcinomas were the most common pathologies 
encountered and complete surgical resection was 
recommended.
Following treatment for LR, all patients in this 
series remain free from recurrence after a median 
follow up of 52 months. Chemo-naive patients 
appear to have been successfully salvaged with 
chemotherapy alone and patients previously 
exposed to cisplatin-based chemotherapy have 
been salvaged with complete surgical excision. 
This is contrary to the experience of most other 
series where outcome following LR is poor. This 
may be because many of these patients had not 
previously been exposed to platinum-based chem-
otherapy, complete excisions were achieved where 
surgery was used, TD, a previously described good 
prognostic indicator, was a frequent pathological 
ﬁ  nding, most patients presented with single site 
late relapse and lastly follow-up time for some of 
the patients is limited.
Conclusions
It is not clear what duration of follow-up is optimal 
for germ cell tumours of the testis. Some groups 
advise lifelong follow-up of all patients with malig-
nant germ cell tumours of the testis though this is 
resource-intensive and the majority of patients do 
not relapse. The Royal Marsden advocates lifelong 
follow-up only in patients who initially presented 
with metastatic disease since this subgroup had a 
higher incidence of LR in their series [Shahidi, 
2002]. Since very few patients with NSGCT relapse 
between 5 and 10 years there is some support for 
limiting follow-up to 5 years. In this cohort of 703 
patients, one patient presented symptomatically 
greater than 10 years from primary treatment, two 
patients symptomatically within 5 years and two 
patients by protocolled CT surveillance within 5 
years. Thus, only one patient (in whom CXR iden-
tiﬁ  ed a mediastinal mass) was picked up by addi-
tional clinic follow-up between 5 and 10 years. 
Patient numbers in this series of Scottish patients 
are small and therefore deﬁ  nitive conclusions can-
not be reached but in view of the valuable resources 
required for this additional follow-up (clinic time, 
x-ray performance and reporting time), unnecessary 
x-ray exposure and patient anxiety, on the basis of 
this small series the beneﬁ  t of follow-up after ﬁ  ve 
years is questionable. Risk factors for relapse 
including an earlier relapse and TD at resection 
should be taken into account when planning the 
duration of follow up. Whenever discharged there 
will always be a small risk of relapse and patients 
should be advised to present promptly should new 
symptoms develop.
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